Psilocybin's Potential Mechanisms in the Treatment of Depression: A Systematic Review

被引:1
作者
Lee, Harrison J. [1 ]
Tsang, Vivian W. L. [1 ]
Chai, Brandon S. [2 ]
Lin, Michelle C. Q. [2 ]
Howard, Andrew [1 ]
Uy, Christopher [3 ]
Elefante, Julius O. [1 ]
机构
[1] Univ British Columbia, Fac Med, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada
[2] Univ British Columbia, Fac Med, Vancouver, BC, Canada
[3] Univ British Columbia, Fac Med, Dept Neurol, Vancouver, BC, Canada
关键词
Psilocybin; Mechanism of action; Treatment; Depression; ANTIDEPRESSANT TREATMENT; INCREASED AMYGDALA; PREFRONTAL CORTEX; PLASTICITY; MOOD; GUIDELINES; GLUTAMATE; DISORDER; ANXIETY; STRESS;
D O I
10.1080/02791072.2023.2223195
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Evidence suggests that psilocybin has therapeutic benefit for treating depression. However, there is little consensus regarding the mechanism by which psilocybin elicits antidepressant effects. This systematic review summarizes existing evidence. Ovid MEDLINE, EMBASE, psychINFO, and Web of Science were searched, for both human and animal studies, using a combination of MeSH Terms and free-text keywords in September 2021. No other mood disorders or psychiatric diagnoses were included. Original papers in English were included. The PRISMA framework was followed for the screening of papers. Two researchers screened the retrieved articles from the literature search, and a third researcher resolved any conflicts. Of 2,193 papers identified, 49 were selected for full-text review. 14 articles were included in the qualitative synthesis. Six supported psilocybin's mechanism of antidepressant action via changes to serotonin or glutamate receptor activity and three papers found an increase in synaptogenesis. Thirteen papers investigated changes in non-receptor or pathway-specific brain activity. Five papers found changes in functional connectivity or neurotransmission, most commonly in the hippocampus or prefrontal cortex. Several neuroreceptors, neurotransmitters, and brain areas are thought to be involved in psilocybin's ability to mitigate depressive symptoms. Psilocybin appears to alter cerebral blood flow to the amygdala and prefrontal cortex, but the evidence on changes in functional connectivity and specific receptor activity remains sparse. The lack of consensus between studies suggests that psilocybin's mechanism of action may involve a variety of pathways, demonstrating the need for more studies on psilocybin's mechanism of action as an antidepressant.
引用
收藏
页码:301 / 315
页数:15
相关论文
共 69 条
  • [41] Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
    McIntyre, Roger S.
    Filteau, Marie-Josee
    Martin, Lawrence
    Patry, Simon
    Carvalho, Andre
    Cha, Danielle S.
    Barakat, maxime
    Miguelez, Maia
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2014, 156 : 1 - 7
  • [42] Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression
    Mertens, Lea J.
    Wall, Matthew B.
    Roseman, Leor
    Demetriou, Lysia
    Nutt, David J.
    Carhart-Harris, Robin L.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2020, 34 (02) : 167 - 180
  • [43] Global trends in the prevalence and incidence of depression:a systematic review and meta-analysis
    Moreno-Agostino, Dario
    Wu, Yu-Tzu
    Daskalopoulou, Christina
    Hasan, M. Tasdik
    Huisman, Martijn
    Prina, Matthew
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2021, 281 : 235 - 243
  • [44] Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies
    Moriguchi, Sho
    Takamiya, Akihiro
    Noda, Yoshihiro
    Horita, Nobuyuki
    Wada, Masataka
    Tsugawa, Sakiko
    Plitman, Eric
    Sano, Yasunori
    Tarumi, Ryosuke
    ElSalhy, Muhammad
    Katayama, Nariko
    Ogyu, Kamiyu
    Miyazaki, Takahiro
    Kishimoto, Taishiro
    Graff-Guerrero, Ariel
    Meyer, Jeffrey H.
    Blumberger, Daniel M.
    Daskalakis, Zafiris J.
    Mimura, Masaru
    Nakajima, Shinichiro
    [J]. MOLECULAR PSYCHIATRY, 2019, 24 (07) : 952 - 964
  • [45] Monoamine Theories of Depression: Historical Impact on Biomedical Research
    Mulinari, Shai
    [J]. JOURNAL OF THE HISTORY OF THE NEUROSCIENCES, 2012, 21 (04) : 366 - 392
  • [46] Methodological quality of case series studies: an introduction to the JBI critical appraisal tool
    Munn, Zachary
    Barker, Timothy Hugh
    Moola, Sandeep
    Tufanaru, Catalin
    Stern, Cindy
    McArthur, Alexa
    Stephenson, Matthew
    Aromataris, Edoardo
    [J]. JBI EVIDENCE SYNTHESIS, 2020, 18 (10) : 2127 - 2133
  • [47] Classical psychedelics for the treatment of depression and anxiety: A systematic review
    Muttoni, Silvia
    Ardissino, Maddalena
    John, Christopher
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2019, 258 : 11 - 24
  • [48] Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis
    Nan-Xi Li
    Yi-Ru Hu
    Wang-Ni Chen
    Zhang, Bin
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2022, 296 : 26 - 34
  • [49] Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study
    Price, Jonathan
    Cole, Victoria
    Goodwin, Guy M.
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2009, 195 (03) : 211 - 217
  • [50] Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model
    Price, Rebecca B.
    Duman, Ronald
    [J]. MOLECULAR PSYCHIATRY, 2020, 25 (03) : 530 - 543